Julian Upton

Sean McCarthy, President & CEO of CytomX, outlines the company’s journey from university startup to rising star of the immuno-oncology space.

Pharm Exec details the latest approaches to combating disease and health crises on a global scale-including industry perspectives from those involved on the front lines.

Killian Weiss talks to Pharm Exec about the modern challenges of identifying KOLs in oncology, and why technology can offer a solution to this vital process.

Andrew Lane, EVP, Established Pharmaceuticals at Abbott, tells Pharm Exec how understanding emerging market dynamics can explain why branded generic medicines are important.

Ahead of today's announcement of the winning entry, Mark Reisenauer, senior vice president, Oncology Business Unit at Astellas, tells PharmExec about the development and objectives of the Astellas Oncology C3 Prize.

Pharm Exec speaks to Prognos CEO Sundeep Bhan about how the company’s unique offering will reach beyond life sciences as the long-promised benefits of AI become reality.

Selecta Biosciences CEO Dr. Werner Cautreels talks about the company's innovative technology and how his entrepreneurial experiences in big pharma prepared him for the challenge of a new startup.

Mary Lynne Hedley, president and COO of TESARO, talks to Pharm Exec about the company’s innovative approach to responsible drug development and commercialization, and how its theory of putting patients first is translated into practise.

Can the pharma industry truly achieve a patient-centric supply chain? How some clinical trial logistics companies are racing ahead in making the patient a key link in the chain.

Dr. Fumie Griego, the International Federation of Pharmaceutical Manufacturers and Associations’ new Assistant Director General, speaks with Pharm Exec about her mission to use IFPMA ’s international reach to find real and practical solutions to the most pressing global healthcare challenges.

Experts assess the current pharma dealmaking landscape-one where, despite market headwinds, is still heavily influenced by factors under the buyer and seller’s control.

With digital interventions in drug adherence regimes evolving to new levels of sophistication, Pharm Exec looks at the ongoing patient-behavior and privacy issues that still present significant challenges.

Q&A spotlights the development of one injection device that is helping change the treatment-adherence landscape.

With the patient voice growing louder in all aspects of the drug development and commercialization journey, Pharm Exec examines some of the current industry thinking on the evolving pharma-patient relationship.

The populist-driven shifts trumpeted from the US to the EU leaves plenty of question marks when trying to size up the trajectory of the global pharma industry. One certainty, however, will be change.

Pharm Exec talks to Mel Formica, Takeda’s Vice President of Global Market Access, about what he sees as the challenges and opportunities in 2017, and how he envisions the industries market access capabilities evolving.

Pharm Exec speaks to ICON's Ramita Tandon about how the UK and European regulators' market access plans for 2017 will affect the industry.

With the push toward value-based heathcare set to accelerate even more in 2017, Takeda’s VP of global market access discusses the evolution of this all-important engine for medical innovation and bottom-line returns.

Pharm Exec speaks with Ramita Tandon, executive vice president, ICON Commercialization & Outcomes, about the potential impact of UK and European regulators’ market access plans for the industry.

“Volume is not a dirty word” was outgoing GSK head Sir Andrew Witty’s key message at last week’s FT Global Pharmaceutical Conference in London.

Pharm Exec sits down with Jeremy Desai, CEO of Apotex, Canada’s largest producer of generic drugs, to discuss the local impact of mounting pricing pressure-and how smaller and independent companies can survive in an era of consolidation and growing competition.

This year’s 19th annual European Health Forum Gastein (Austria) once again attempted to establish unity in the face of EU woes. But are the Gastein region’s “healing powers” on the wane?

President, Global Vaccines, Merck & Co.

The UK's vote to leave the EU was the hot topic - and a source of exasperation - at last week's annual European Health Forum Gastein.

If Richard Bergström was not already planning his departure as Director General of EFPIA, his participation in a panel session at last week’s European Health Forum Gastein might have pushed him towards it.

Global Head, Drug Development, and Chief Medical Officer, Novartis

Vice President, Business Technology, Pfizer Inc.

Envigo's new CEO shares with Pharm Exec his vision for the company’s future, the changes he’s seen in the industry, and his thoughts on that thorny subject, Brexit.

Pharm Exec talks to AstraZeneca's Jenny Streets about the new AZHelps mobile and social media platform.

European pharma is bracing itself for EFPIA’s June deadline requiring the disclosure of transfer-of-value transactions make to HCPs. Pharm Exec looks at how the industry is preparing for this historic moment.